Brief: Urogen Says Ugn-102 Met Primary Endpoints In Two Phase 3 Trials

UroGen Pharma

27/07/2023 15:30

July 27 (Reuters) - Urogen Pharma Ltd  UR8.F :
    * UGN-102, IN DEVELOPMENT AS THE POTENTIAL FIRST
NON-SURGICAL
THERAPY FOR LG-IR-NMIBC, MET PRIMARY ENDPOINTS IN BOTH PHASE 3
ATLAS AND ENVISION CLINICAL TRIALS
    * UROGEN PHARMA LTD- ARE ON TRACK TO DELIVER ON OUR
PREVIOUSLY
SHARED GUIDANCE FOR JELMYTO

Source text for Eikon:  ID:nBwc9m38za 
Further company coverage:  UR8.F 

 ((Reuters.Briefs@thomsonreuters.com;))